← Back to headlines
Revolution Medicines Updates 2026 Operating Expenses and Prepares for Daraxonrasib Launch
Revolution Medicines has updated its 2026 GAAP operating expense guidance to $2.1 billion-$2.2 billion as it prepares for the potential launch of daraxonrasib.
5 Aug, 23:01 — 5 Aug, 23:01
Sources
Showing 1 of 1 sources
